← 返回

癌症免疫治疗的新进展

英文原题:The new progress in cancer immunotherapy.

查看英文原题

The new progress in cancer immunotherapy.

PubMed 2022/09/15(内容时间) Clin Exp Med Q2 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤微环境中免疫细胞与非免疫细胞之间的相互作用导致免疫抑制,从而促进肿瘤生长和存活。免疫治疗是一种先进的治疗方法,它增强体液免疫和细胞免疫,而不是使用与脱靶和非特异性靶点以及对正常细胞有毒副作用相关的化疗或放疗策略。免疫检查点抑制剂和基于 T 细胞的免疫治疗已经对实体瘤和白血病显示出显著效果。逃避免疫监视的肿瘤细胞是癌症患者获得有效免疫应答的主要障碍。近年来,在广泛的固有免疫和适应性免疫检查点方面取得了巨大进展,这些检查点在预防肿瘤发生中发挥重要作用,因此可能成为抑制肿瘤细胞生长的潜在靶点。本综述旨在总结现有免疫治疗方法(包括 T 细胞和 NK 来源的免疫检查点治疗,以及其他内在检查点和吞噬检查点)的潜在分子机制。总之,这些见解将为未来开发高效新疗法的新的固有免疫和适应性免疫调节靶点铺平道路。

展开英文摘要原文

The cross talk between immune and non-immune cells in the tumor microenvironment leads to immunosuppression, which promotes tumor growth and survival. Immunotherapy is an advanced treatment that boosts humoral and cellular immunity rather than using chemotherapy or radiation-based strategy associated with non-specific targets and toxic effects on normal cells. Immune checkpoint inhibitors and T cell-based immunotherapy have already exhibited significant effects against solid tumors and leukemia.

Tumor cells that escape immune surveillance create a major obstacle to acquiring an effective immune response in cancer patients. Tremendous progress had been made in recent years on a wide range of innate and adaptive immune checkpoints which play a significant role to prevent tumorigenesis, and might therefore be potential targets to suppress tumor cells growth.

This review aimed to summarize the underlying molecular mechanisms of existing immunotherapy approaches including T cell and NK-derived immune checkpoint therapy, as well as other intrinsic and phagocytosis checkpoints.

Together, these insights will pave the way for new innate and adaptive immunomodulatory targets for the development of highly effective new therapy in the future.

论文信息

作者
Shimu AS、Wei HX、Li Q、Zheng X、Li B
第一作者单位
Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, China.China
通讯作者单位
Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, China. libf@ustc.edu.cn.China
文献类型
综述
期刊
Clinical and experimental medicine2023 Jul
原文标识
PubMed 36109471 · DOI 10.1007/s10238-022-00887-0